Clinical Trial Update: pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab with pBI-11 and TA-HPV for advanced, HPV-positive, PD-L1 CPS≥1 oropharyngeal cancer; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oropharyngeal Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Michael K. Gibson | Conditions: Metastatic Oropharyngeal Carcinoma, Recurrent Oropharyngeal Carcinoma | Phase 2 | Status: RECRUITING